First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study
Introduction : Event rates after percutaneous coronary interventions (PCI) are higher in small than large coronary vessels but may vary between different drug-eluting stent (DES) types. Aim : To assess the efficacy of two different DES in small vessel disease. Material and methods : Patients wit...
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Termedia Publishing House
2016-11-01
|
| 丛编: | Advances in Interventional Cardiology |
| 主题: | |
| 在线阅读: | https://www.termedia.pl/First-generation-paclitaxel-vs-second-generation-zotarolimus-eluting-stents-in-small-coronary-arteries-the-BASKET-SMALL-Pilot-Study,35,28687,1,1.html |
| _version_ | 1828423500150341632 |
|---|---|
| author | Raban Jeger Matthias Pfisterer Otmar Pfister Peter Rickenbacher Michael Handke Nicole Gilgen Michael Coslovsky Christoph Kaiser |
| author_facet | Raban Jeger Matthias Pfisterer Otmar Pfister Peter Rickenbacher Michael Handke Nicole Gilgen Michael Coslovsky Christoph Kaiser |
| author_sort | Raban Jeger |
| collection | DOAJ |
| description | Introduction : Event rates after percutaneous coronary interventions (PCI) are higher in small than large coronary vessels but may vary between different drug-eluting stent (DES) types.
Aim : To assess the efficacy of two different DES in small vessel disease.
Material and methods : Patients with small vessel PCI were randomised 1 : 1 to a first-generation paclitaxel- vs. a second-generation zotarolimus-eluting stent. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularisation after 2 years.
Results: Overall, 191 patients were enrolled: 100 with a paclitaxel- and 91 with a zotarolimus-eluting stent. Baseline characteristics were similar in both groups. After 2 years, rates of the primary endpoint were numerically higher for zotarolimus- than paclitaxel-eluting stents (9.9% vs. 5.0%, hazard ratio 2.09, 95% confidence interval (CI) 0.7–6.2, p = 0.19), which was mainly driven by higher rates of target vessel revascularisation (6.6% vs. 2.0%, hazard ratio 3.39, 95% CI: 0.68–16.78, p = 0.14). Based on this, a total of 1,019 patients would be necessary to demonstrate at least non-inferiority between the DES used.
Conclusions : In this pilot study, paclitaxel-eluting stents had a favourable efficacy profile in small vessel disease, although the numbers were too small to draw final conclusions. Based on the prohibitively high sample size for a randomized controlled trial between DES, other treatment options should be considered. |
| first_indexed | 2024-12-10T16:02:18Z |
| format | Article |
| id | doaj.art-b3ecab4986c0417caf4ee1d2f21c0bcd |
| institution | Directory Open Access Journal |
| issn | 1734-9338 1897-4295 |
| language | English |
| last_indexed | 2024-12-10T16:02:18Z |
| publishDate | 2016-11-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Advances in Interventional Cardiology |
| spelling | doaj.art-b3ecab4986c0417caf4ee1d2f21c0bcd2022-12-22T01:42:23ZengTermedia Publishing HouseAdvances in Interventional Cardiology1734-93381897-42952016-11-0112431432010.5114/aic.2016.6363028687First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot StudyRaban JegerMatthias PfistererOtmar PfisterPeter RickenbacherMichael HandkeNicole GilgenMichael CoslovskyChristoph KaiserIntroduction : Event rates after percutaneous coronary interventions (PCI) are higher in small than large coronary vessels but may vary between different drug-eluting stent (DES) types. Aim : To assess the efficacy of two different DES in small vessel disease. Material and methods : Patients with small vessel PCI were randomised 1 : 1 to a first-generation paclitaxel- vs. a second-generation zotarolimus-eluting stent. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularisation after 2 years. Results: Overall, 191 patients were enrolled: 100 with a paclitaxel- and 91 with a zotarolimus-eluting stent. Baseline characteristics were similar in both groups. After 2 years, rates of the primary endpoint were numerically higher for zotarolimus- than paclitaxel-eluting stents (9.9% vs. 5.0%, hazard ratio 2.09, 95% confidence interval (CI) 0.7–6.2, p = 0.19), which was mainly driven by higher rates of target vessel revascularisation (6.6% vs. 2.0%, hazard ratio 3.39, 95% CI: 0.68–16.78, p = 0.14). Based on this, a total of 1,019 patients would be necessary to demonstrate at least non-inferiority between the DES used. Conclusions : In this pilot study, paclitaxel-eluting stents had a favourable efficacy profile in small vessel disease, although the numbers were too small to draw final conclusions. Based on the prohibitively high sample size for a randomized controlled trial between DES, other treatment options should be considered.https://www.termedia.pl/First-generation-paclitaxel-vs-second-generation-zotarolimus-eluting-stents-in-small-coronary-arteries-the-BASKET-SMALL-Pilot-Study,35,28687,1,1.htmlsmall vessel disease drug-eluting stent paclitaxel zotarolimus |
| spellingShingle | Raban Jeger Matthias Pfisterer Otmar Pfister Peter Rickenbacher Michael Handke Nicole Gilgen Michael Coslovsky Christoph Kaiser First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study Advances in Interventional Cardiology small vessel disease drug-eluting stent paclitaxel zotarolimus |
| title | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
| title_full | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
| title_fullStr | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
| title_full_unstemmed | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
| title_short | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
| title_sort | first generation paclitaxel vs second generation zotarolimus eluting stents in small coronary arteries the basket small pilot study |
| topic | small vessel disease drug-eluting stent paclitaxel zotarolimus |
| url | https://www.termedia.pl/First-generation-paclitaxel-vs-second-generation-zotarolimus-eluting-stents-in-small-coronary-arteries-the-BASKET-SMALL-Pilot-Study,35,28687,1,1.html |
| work_keys_str_mv | AT rabanjeger firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT matthiaspfisterer firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT otmarpfister firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT peterrickenbacher firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT michaelhandke firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT nicolegilgen firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT michaelcoslovsky firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy AT christophkaiser firstgenerationpaclitaxelvssecondgenerationzotarolimuselutingstentsinsmallcoronaryarteriesthebasketsmallpilotstudy |